Related Experiment Video
Updated: Aug 12, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
Antiretroviral therapy and resistance to antiretroviral drugs
Joep M A Lange1, Remko van Leeuwen
1International Antiviral Therapy Evaluation Centre (IATEC), Academic Medical Center/University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
Abstract:
Slightly more than a decade after the discovery of HIV as the causative agent of AIDS, effective therapies against this virus have become available. Because of a large degree of cross-resistance among antiretroviral agents in the same class (nRTIs, NNRTIs, or PIs), once a therapy has failed virologically, future therapeutic options with currently available drugs are limited, however. Poor tolerability and toxicity may also compromise the long-term prospects of antiretroviral therapy. Nevertheless, benefits of antiretroviral therapy far outweigh the downsides and efforts to scale up responsible use of antiretroviral agents in developing countries are a priority in the fight against HIV/AIDS. This paper presents an overview of antiretroviral therapy and resistance to antiretroviral drugs.
Related Concept Videos
Retrovirus Life Cycles
Viral Mutations
Treatment Resistant Cancers
Inhibitors of Viral Protein Synthesis
Antiviral Nucleoside Inhibitors
Inhibitors of Virion Maturation and Assembly

